JP Morgan Chase
PHAT icon

JP Morgan Chase’s Phathom Pharmaceuticals PHAT Stock Holding History

JP Morgan Chase’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99M Sell
275,251
-12,179
-4% -$139K ﹤0.01% 3884
2026
Q1 		$3.03M Sell
287,430
-9,254
-3% -$117K ﹤0.01% 3767
2025
Q4 		$4.92M Buy
296,684
+159,736
+117% +$2.28M ﹤0.01% 3329
2025
Q3 		$1.61M Sell
136,948
-1,568
-1% -$16.2K ﹤0.01% 4244
2025
Q2 		$1.33M Buy
138,516
+1,123
+0.8% +$6.21K ﹤0.01% 4213
2025
Q1 		$861K Buy
137,393
+486
+0.4% +$2.95K ﹤0.01% 4453
2024
Q4 		$1.11M Buy
136,907
+1,476
+1% +$18.3K ﹤0.01% 4557
2024
Q3 		$2.45M Buy
135,431
+1,074
+0.8% +$15K ﹤0.01% 3847
2024
Q2 		$1.38M Sell
134,357
-4,095
-3% -$42.2K ﹤0.01% 4053
2024
Q1 		$1.47M Sell
138,452
-7,585
-5% -$64.4K ﹤0.01% 4074
2023
Q4 		$1.33M Buy
146,037
+1,281
+0.9% +$11K ﹤0.01% 4135
2023
Q3 		$1.5M Buy
144,756
+10,760
+8% +$148K ﹤0.01% 3778
2023
Q2 		$1.92M Buy
133,996
+409
+0.3% +$4.72K ﹤0.01% 3577
2023
Q1 		$954K Buy
133,587
+4,438
+3% +$39K ﹤0.01% 4073
2022
Q4 		$1.45M Sell
129,149
-42,221
-25% -$435K ﹤0.01% 3808
2022
Q3 		$1.9M Buy
171,370
+583
+0.3% +$5.55K ﹤0.01% 3517
2022
Q2 		$1.44M Sell
170,787
-4,775
-3% -$49.1K ﹤0.01% 3822
2022
Q1 		$2.39M Buy
175,562
+3,001
+2% +$48.5K ﹤0.01% 3616
2021
Q4 		$3.39M Buy
172,561
+3,573
+2% +$84.1K ﹤0.01% 3377
2021
Q3 		$5.42M Buy
168,988
+156,643
+1,269% +$5.21M ﹤0.01% 2969
2021
Q2 		$418K Sell
12,345
-182,029
-94% -$6.52M ﹤0.01% 4810
2021
Q1 		$7.3M Buy
194,374
+7,368
+4% +$308K ﹤0.01% 2639
2020
Q4 		$6.21M Buy
187,006
+24,411
+15% +$989K ﹤0.01% 2619
2020
Q3 		$5.82M Buy
162,595
+2,476
+2% +$85.7K ﹤0.01% 2439
2020
Q2 		$5.27M Buy
160,119
+156,575
+4,418% +$6.02M ﹤0.01% 2413
2020
Q1 		$91K Buy
3,544
+35
+1% +$1.17K ﹤0.01% 4549
2019
Q4 		$109K Buy
+3,509
New +$88.2K ﹤0.01% 4869

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

JP Morgan Chase's PHAT Position: Q2 2026 in Review

JP Morgan Chase reduced its Phathom Pharmaceuticals (PHAT) stake by 4.2% in Q2 2026, selling an estimated $139K and leaving 275,251 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #3884.

JP Morgan Chase first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $7.3M in Q1 2021. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • JP Morgan Chase held 275,251 shares of Phathom Pharmaceuticals worth $2.99M as of Q2 2026.
  • JP Morgan Chase sold 12,179 Phathom Pharmaceuticals shares in Q2 2026, an estimated $139K.
  • Phathom Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3884 holding.
  • JP Morgan Chase first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Phathom Pharmaceuticals position peaked at $7.3M in Q1 2021.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.